Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$26.33 USD
+0.83 (3.25%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $26.36 +0.03 (0.11%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
PCRX 26.33 +0.83(3.25%)
Will PCRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCRX
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
Pacira (PCRX) Matches Q4 Earnings Estimates
Acadia Healthcare (ACHC) Q4 Earnings and Revenues Surpass Estimates
Other News for PCRX
Commit To Buy Pacira BioSciences At $17.50, Earn 10.4% Annualized Using Options
Noteworthy Tuesday Option Activity: PCRX, CMG, CVNA
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Understanding Key Factors Behind Pacira Pharmaceuticals’ Analyst Rating
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)